SynAct Pharma Publishes 2025 Annual Report on Inflammatory Disease Pipeline

SynAct Pharma AB ( (SE:SYNACT) ) has shared an announcement.

SynAct Pharma AB has published its annual report for the financial year 2025, covering the consolidated and parent company financial statements, governance structure and key operational information. The report outlines the company’s clinical-stage focus on melanocortin-based immunotherapies for inflammatory diseases, its intellectual property position and market opportunities, and provides stakeholders with an overview of significant events, financial performance and corporate oversight during the year.

The disclosure of comprehensive financial statements and governance reports underscores SynAct’s efforts to maintain transparency as it advances its pipeline and manages its capital structure. For investors and other stakeholders, the annual report serves as a key reference on the company’s operational progress, risk profile and strategic positioning in the competitive inflammatory disease treatment landscape.

More about SynAct Pharma AB

SynAct Pharma AB is a clinical-stage biopharmaceutical company focused on developing drugs that stimulate and strengthen the body’s own immune system to treat inflammatory diseases. The group comprises the Swedish parent company and wholly owned subsidiaries in Denmark and Switzerland, positioning it within the immunology and inflammatory disorder therapeutics market.

Average Trading Volume: 189,937

Technical Sentiment Signal: Sell

Current Market Cap: SEK927.9M

See more data about SYNACT stock on TipRanks’ Stock Analysis page.